Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19.

Neima BriggsMichael V GormallyFangyong LiSabrina L Browning Miriam M TreggiariAlyssa MorrisonMaudry Laurent-RolleYanhong DengJeanne E HendricksonChristopher A TormeyMahalia S Desruisseaux

Published in: PloS one (2021)

Early administration of CCP improves outcomes in patients with moderate-to-severe COVID-19, while improvement was not observed with late CCP administration. The importance of timing of administration should be addressed in specifically designed trials.

Keyphrases

coronavirus disease
sars cov
high intensity
early onset
type diabetes
respiratory syndrome coronavirus
drug induced
insulin resistance
weight loss